Stroke is a leading cause of death and disability.
1 In acute ischemic stroke, thrombolysis with intravenous tissue plasminogen activator (tPA) is the treatment of choice after exclusion of intracerebral hemorrhage by brain imaging.
2 Neurons die rapidly during ischemia, and randomized placebo-controlled trials have shown time-dependent benefits of tPA: early treatment is associated with better outcomes.
3-7 Within 90 minutes of symptom onset, the number needed to treat for 1 excellent outcome is 4.5; the number is 9 between 91 and 180 minutes and 14 between 181 and 270 minutes.
5 However, only a minority of stroke patients receive tPA,
8 and in a European stroke registry only 11% of this minority were treated within the first 90 minutes.
9 Apart from delayed patient response, prehospital and intrahospital management (“onset-to-door” and “door-to-needle”) contribute to delays. Onset-to-door times range from 46 to 150 minutes,
10 and recent data from the United States indicate that less than 30% of patients have a door-to-needle time within the recommended 60 minutes.
2,8 Recently, one study reported time saving in 12 tPA administrations performed in a special ambulance with integrated computed tomography (CT) scanner and point-of-care laboratory.
11 Little is known about the overall effects and risks of specialized ambulances for patients with stroke and also for patients with other diseases. After a 3-month pilot study with the Stroke Emergency Mobile (STEMO),
12 we investigated the effects of its deployment on time to treatment and safety in a larger controlled study.
13